Cargando…

Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates

BACKGROUND: Anti-programmed death 1 (PD1)/programmed cell death ligand 1 (PD-L1) therapies have shown modest activity as monotherapy in recurrent ovarian cancer. Platinum chemotherapies induce T-cell proliferation and enhance tumor recognition. We assessed activity and safety of pembrolizumab with c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, John B, Gwin, William R, Urban, Renata R, Hitchcock-Bernhardt, Katie M, Coveler, Andrew L, Higgins, Doreen M, Childs, Jennifer S, Shakalia, Hania N, Swensen, Ron E, Stanton, Sasha E, Tinker, Anna V, Wahl, Tanya A, Ancheta, Richard G, McGonigle, Kathryn F, Dai, James Y, Disis, Mary L, Goff, Barbara A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449961/ https://www.ncbi.nlm.nih.gov/pubmed/34531249 http://dx.doi.org/10.1136/jitc-2021-003122

Ejemplares similares

T057: Circulating tumor DNA in classical Hodgkin lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume
por: Lynch, Ryan C., et al.
Publicado: (2022)

P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
por: Borchmann, Peter, et al.
Publicado: (2022)

T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment
por: Timmerman, John, et al.
Publicado: (2022)

Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma
por: Nishihori, Taiga, et al.
Publicado: (2022)

Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer
por: Chun, Brie, et al.
Publicado: (2022)

Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab
por: Watson, Geoffrey Alan, et al.
Publicado: (2022)

Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab
por: Routh, Eric D, et al.
Publicado: (2023)

Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
por: Cristescu, Razvan, et al.
Publicado: (2022)

Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis
por: Kawai, Taketo, et al.
Publicado: (2022)

Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
por: Haddad, Robert I, et al.
Publicado: (2022)

Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)
por: Ricciuti, Biagio, et al.
Publicado: (2021)

PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis
por: Lo Russo, Giuseppe, et al.
Publicado: (2023)

Carboplatin/pembrolizumab/pemetrexed: COVID-19 pneumonia: case report
Publicado: (2021)

Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer
por: Egelston, Colt, et al.
Publicado: (2021)

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
por: Goswami, Meghali, et al.
Publicado: (2022)

Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer
por: Alessi, Joao V, et al.
Publicado: (2021)

Phase 2 study of pembrolizumab in patients with advanced rare cancers
por: Naing, Aung, et al.
Publicado: (2020)

Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial
por: Ellingsen, Espen B., et al.
Publicado: (2023)

Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma
por: Bedrose, Sara, et al.
Publicado: (2020)

Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma
por: Lurain, Kathryn, et al.
Publicado: (2021)

Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers
por: Colen, Rivka R, et al.
Publicado: (2021)

Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors
por: Hurkmans, Daan P., et al.
Publicado: (2021)

IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation
por: Rozeman, Elisa A, et al.
Publicado: (2023)

Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study
por: Taylor, Matthew H., et al.
Publicado: (2022)

Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial
por: Verset, Gontran, et al.
Publicado: (2022)

Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
por: Shoushtari, Alexander N., et al.
Publicado: (2023)

Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival
por: de Klerk, Leonie K, et al.
Publicado: (2021)

Clinical significance of tumor-infiltrating lymphocytes in breast cancer
por: Stanton, Sasha E., et al.
Publicado: (2016)

A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
por: Hayashi, Hidetoshi, et al.
Publicado: (2022)

Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
por: Davar, Diwakar, et al.
Publicado: (2022)

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
por: Vasey, P A, et al.
Publicado: (2008)

(89)Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs
por: van der Veen, Elly L, et al.
Publicado: (2020)

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
por: Wong, Jeffrey Sum Lung, et al.
Publicado: (2021)

Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors
por: Rahma, Osama E, et al.
Publicado: (2022)

Responses of metastatic primary fallopian tube carcinoma to pembrolizumab and nab-paclitaxel: A case report
por: Jiang, Jian, et al.
Publicado: (2020)

T-cell tolerant fraction as a predictor of immune-related adverse events
por: Ostmeyer, Jared, et al.
Publicado: (2023)

Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers
por: Naidoo, Jarushka, et al.
Publicado: (2021)

Concurrent SPECT/PET-CT imaging as a method for tracking adoptively transferred T-cells in vivo
por: Stanton, Sasha E., et al.
Publicado: (2016)

Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

Genomic data and the dividual self
por: McGonigle, Ian
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9tu585sugn2p9u3l724dt9fsca